The NIH's National Institute of Allergy and Infectious Diseases has awarded a five-year, $15.5 million grant to Inviragen and PharmaJet to develop a needleless vaccine that can offer protection against all four strains of dengue virus. Inviragen's DENVax vaccine can be administered using PharmaJet's injector that uses pressurized liquid in drug delivery.

Related Summaries